RT Journal Article
SR Electronic
T1 Effects of pharmacogenomic (PGx) testing on clinical pain management prescriptions, a retrospective study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.21.21258931
DO 10.1101/2021.06.21.21258931
A1 Christian Tagwerker
A1 Mary Jane Carias-Marines
A1 David J. Smith
YR 2021
UL http://medrxiv.org/content/early/2021/06/28/2021.06.21.21258931.abstract
AB Current deficits in effectively utilizing PGx testing in clinical practice include limited awareness and training of healthcare professionals, routine ordering of assays investigating up to 5 genes and lack of concise reporting of dosing guidelines and drug-drug-interactions. A novel deep sequencing (>1000X) PGx panel is described encompassing 23 genes and 141 SNPs or indels combined with PGx dosing guidance, drug-gene-interaction (DGI) and drug-drug-interaction (DDI) reporting to prevent adverse drug reaction events. During a 2-year period, patients (n = 171) were monitored in a pain management clinic. Urine toxicology, PGx reports, and progress notes were studied retrospectively for changes in prescription regimens before and after the PGx report was made available to the provider.Among patient PGx reports with medication lists provided (n = 146) 57.5% showed one or more moderate and 5.5% at least one serious pharmacogenetic interaction. 66% of patients showed at least one moderate and 15% one or more serious drug-gene or drug-drug-interaction. A significant number of active changes in prescriptions based on the PGx reports provided was observed for 85 patients (83%) for which a specific drug was either discontinued, switched within the defined drug classes of the report or a new drug added.Preventative action was observed for all serious interactions and only moderate interactions were tolerated for lack of other alternatives. This study demonstrates a successful implementation of PGx testing utilizing an extended PGx panel combined with a customized, informational report to help improve clinical outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the Declaration of Helsinki with written informed consent from each patient. Patient data collection and summaries were approved by the Alcala Pharmaceutical Inc. Institutional Review Board (IORG0010127, IRB00012026, #R003). All test samples derived from human subjects were de-identified of their health information as defined by HIPAA guidelines. Patient data for comparison of urine drug adherence testing before and after PGx reporting were obtained retrospectively from patients (n = 171) during routine testing in a pain management clinic representing an ethnically diverse patient population served by Alcala Testing and Analysis Services (ATAS) from 2016 to 2018 within the western United States. Available data includes de-identified pre- and post-PGx medication lists, PGx and urine drug adherence data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study was conducted in accordance with the Declaration of Helsinki with written informed consent from each patient. Patient data collection and summaries were approved by the Alcala Pharmaceutical Inc. Institutional Review Board (IORG0010127, IRB00012026, #R003). All test samples derived from human subjects were de-identified of their health information as defined by HIPAA guidelines. Patient data for comparison of urine drug adherence testing before and after PGx reporting were obtained retrospectively from patients (n = 171) during routine testing in a pain management clinic representing an ethnically diverse patient population served by Alcala Testing and Analysis Services (ATAS) from 2016 to 2018 within the western United States. Available data includes de-identified pre- and post-PGx medication lists, PGx and urine drug adherence data.